AdaptHealth stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 70 to 81.
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of over 80 in the early stages of their moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Is AdaptHealth Stock A Buy?
AdaptHealth stock is trying to complete a consolidation with an 11.90 buy point. See if it can clear the breakout price in volume at least 40% above average.
Earnings growth rose last quarter from 0% to 44%. But sales fell from 6% to 2%.
AdaptHealth stock earns the No. 7 rank among its peers in the Medical-Outpatient/Home Care industry group. Addus HomeCare, DaVita and Encompass Health are among the top 5 highly rated stocks within the group.
